Effects Of First-generation Targeted Drugs On Blood Coagulation In Patients With Advanced Non-small Cell Lung Cancer

Objective: the purpose of this study was to investigate the effects of first-generation targeted drugs(gefitinib and ectinib)on coagulation in patients with advanced NSCLC.Methods: During 2017-2019,we selected 42 NSCLC patients who had taken gefitinib or ectinib as the experimental group,and selected 40 NSCLC patients who were refused treatment during the same period as the control group,we compared the differences in blood coagulation function between the two groups and recorded the adverse events of the patients.Results: Compared with control group,experimental group patients of thrombin time(TT),activeted partial thromboplastin time(APTT)live enzymes significantly shortened(P < 0.05),prothrombin time(PT)has a tendency to extend,but no statistical difference,the experimental group patients after D-Dimer(D-D),platelet(PLT)is significantly higher than control group(P < 0.05)and fibrinogen(FIB)decreased significantly(P <0.05),the experimental group patients the incidence of adverse events was4.7%,the treatment used in the experimental group of patients and use ek for patients,no difference between the related parameters of bloodcoagulation.Conclusion: NSCLC patients can maintain a high coagulation state during the use of first-generation targeted drugs,which increases the incidence of thrombotic adverse events.